RTH258. “Son of Lucentis.” The drug is brolucizumab – a single-chain antibody fragment, a potent inhibitor of VEGF, and it’s claimed to be “the smallest known active unit of an antibody.” It also holds the potential of a 12-weekly treatment interval for the treatment of AMD, which, if true, clearly means fewer hospital visits for patients and an easing of the burden for the healthcare professionals that have to run the clinics. Last month, at the American Academy of Ophthalmology annual meeting in New Orleans, Pravin Dugel presented the much-anticipated 48-week data from the 96-week, Phase III evaluation of two doses of the intravitreally-administered anti-VEGF drug compared with aflibercept for the treatment of neovascular AMD in the HAWK and HARRIER trials (1).

The trial design, treatment regimens and disease activity assessments are depicted in Figure 1, and consisted of two phases: an initial 16-week matched regimen period to provide a head-to-head comparison of brolucizumab (3.0 or 6.0 mg) and aflibercept 2.0 mg, which was followed by brolucizumab being dosed in 12-weekly intervals (q12w) – reduced to 8-weekly intervals (q8w), if signs of disease activity were noted. Patients randomized to receive aflibercept were administered q8w doses for the rest of the study.

Figure 1. HAWK/HARRIER trial design. *Disease activity assessments were conducted at pre-specified visits by the masked investigator, supported by protocol guidance based on dynamic functional and anatomical characteristics. Additional assessments and potential dosing interval adjustments occurred at weeks 28, 40, 52, 64, 76 and 88 in the HARRIER study. Figure 2. Mean change in BCVA letters at week 48 in the HAWK and HARRIER trials. Brolucizumab (q8w/q12w) was non-inferior to aflibercept at both doses for this endpoint. *Noninferiority with a 4.0 letter margin vs aflibercept; noninferiority for change in BCVA from baseline averaged over period of Week 36–43 in HAWK (brolucizumab 3.0 mg p=0.0001; brolucizumab 6.0 mg (p<0.0001) and HARRIER (p<0.0003) vs. aflibercept).

So what does the 48-week data show? Brolucizumab met the primary (non-inferiority) endpoint: change in BCVA from baseline to week 48 (Figure 2). Not all patients were able to maintain the q12w brolucizumab treatment interval – in HAWK, 52 and 57 percent of patients remained on q12w for the 3.0 and 6.0 mg doses, respectively. And in HARRIER (which evaluated only the 6.0 mg brolucizumab dose), 52 percent of patients remained on the longer interval by week 48. However, the visual gains achieved by all drugs and dosing arms were robust in the head-to-head assessment period, and were maintained out to week 48. Additionally, significantly (p<0.05) fewer brolucizumab-receiving patients displayed disease activity at week 16 (HAWK: 27.4, 23.5 and 33.5 percent for brolucizumab 3.0 mg, 6.0 mg and aflibercept 2.0 mg, respectively; HARRIER: 21.9 vs. 31.4 percent). In both trials, the novel agent was also found to have achieved superior reductions in central subfield thickness measurements in both the head-to-head and maintenance phases, and significantly fewer brolucizumab-receiving patients had intraretinal, subretinal or sub-RPE fluid on assessment at week 16 or 48. In terms of safety, ocular, non-ocular and serious adverse event rates were similar across treatment groups.

Can brolucizumab stretch those treatment intervals out beyond what’s currently achievable? On the basis of the HAWK/HARRIER trial data, it seems that for some patients, at least, the answer could be “yes.” Dugel stated in his presentation that further details of the HAWK and HARRIER trials will be presented in future congresses – and it was clear that those details are keenly awaited.